Cargando…
Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study
This study was performed to assess the efficacy and safety of preoperative chemoradiation consisting of carboplatin and paclitaxel and concurrent radiotherapy for patients with resectable (T2-3N0-1M0) oesophageal cancer. Treatment consisted of paclitaxel 50 mg m(−2) and carboplatin AUC=2 on days 1,...
Autores principales: | van Meerten, E, Muller, K, Tilanus, H W, Siersema, P D, Eijkenboom, W M H, van Dekken, H, Tran, T C K, van der Gaast, A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361286/ https://www.ncbi.nlm.nih.gov/pubmed/16670722 http://dx.doi.org/10.1038/sj.bjc.6603134 |
Ejemplares similares
-
Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer
por: Polee, M B, et al.
Publicado: (2002) -
Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer
por: Gaast, A van der, et al.
Publicado: (1999) -
A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma
por: Xia, Yi, et al.
Publicado: (2018) -
Clinical Outcome in Definitive Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Locally Advanced Esophageal and Junctional Cancer
por: Noronha, Vanita, et al.
Publicado: (2016) -
Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS)
por: van Heijl, M, et al.
Publicado: (2008)